2024
Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity
Barbieri E, Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Van Name M, Samuels S, Caprio S, Sabati M, Galderisi A, Sherr J, Man C, Santoro N. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity 2024, 33: 116-124. PMID: 39658509, PMCID: PMC11666407, DOI: 10.1002/oby.24175.Peer-Reviewed Original ResearchConceptsIntrahepatic fat contentDaily glucose variabilityLiver proton density fat fractionProton density fat fractionGlucose variabilityInsulin sensitivityOral glucose tolerance testFat fractionInsulin secretionAssociated with insulin resistanceFirst-phase insulin secretionAssociated with 2-h glucoseGlucose tolerance testGlucose standard deviationMagnetic resonance imagingOral minimal modelCoefficient of variationBasal insulin secretionPediatric obesityPostprandial glucoseTolerance testCell sensitivityInsulin resistanceObesityResonance imaging
2023
OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals
Ylescupidez A, Speake C, Pietropaolo S, Wilson D, Steck A, Sherr J, Gaglia J, Bender C, Lord S, Greenbaum C. OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals. The Journal Of Clinical Endocrinology & Metabolism 2023, 109: 57-67. PMID: 37572381, PMCID: PMC10735531, DOI: 10.1210/clinem/dgad472.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringClinical trialsPositive individualsOral glucose tolerance testPrediction of T1DGlucose tolerance testType 1 diabetesCGM dataTrialNet PathwayMultiple autoantibodiesT1D diagnosisTolerance testAncillary studiesContinuous glucose monitoring dataMultivariable modelCGM metricsInsufficient evidenceAcademic centersGlucose monitoring dataHigh discriminative abilityT1D predictionGlucose monitoringCGM measuresCharacteristic curveOGTTCGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.
Wilson D, Pietropaolo S, Acevedo-Calado M, Huang S, Anyaiwe D, Scheinker D, Steck A, Vasudevan M, McKay S, Sherr J, Herold K, Dunne J, Greenbaum C, Lord S, Haller M, Schatz D, Atkinson M, Nelson P, Pietropaolo M. CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. Diabetes Care 2023, 46: 526-534. PMID: 36730530, PMCID: PMC10020029, DOI: 10.2337/dc22-1297.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testNormal oral glucose tolerance testType 1 diabetesDiabetes-related autoantibodiesGlucose levelsCGM metricsTrialNet PathwayPrevention StudyAbnormal oral glucose tolerance testGlucose valuesGlucose tolerance testContinuous glucose monitoring parametersStage 2 participantsRelatives of individualsCGMS assessmentDysglycemic statesTolerance testIdentification of individualsDiabetesNegative testAutoantibodiesProgressionBaseline dataIndividualsParticipants